p53 small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts

Eduard B. Dinca, Kan V. Lu, Jann N Sarkaria, Russell O. Pieper, Michael D. Prados, Daphne A. Haas-Kogan, Scott R. VandenBerg, Mitchel S. Berger, C. David James

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

In this study, we investigated the precursor and active forms of a p53 small-molecule inhibitor for their effects on temozolomide (TMZ) antitumor activity against glioblastoma (GBM), using both in vitro and in vivo experimental approaches. Results from in vitro cell viability analysis showed that the cytotoxic activity of TMZ was substantially increased when p53 wild-type (p53wt) GBMs were cotreated with the active form of p53 inhibitor, and this heightened cytotoxic response was accompanied by increased poly(ADP-ribose) polymerase cleavage as well as elevated cellular phospho-H2AX. Analysis of the same series of GBMs, as intracranial xenografts in athymic mice, and administering corresponding p53 inhibitor precursor, which is converted to the active compound in vivo, yielded results consistent with the in vitro analyses: TMZ + p53 inhibitor precursor cotreatment of three distinct p53 wt GBM xenografts resulted in significant enhancement of TMZ antitumor effect relative to treatment with TMZ alone, as indicated by serial bioluminescence monitoring as well as survival analysis (P < 0.001 for cotreatment survival benefit in each case). Mice receiving intracranial injection with p53null GBM showed similar survival benefit from TMZ treatment regardless of the presence or absence of p53 inhibitor precursor. In total, our results indicate that the p53 active and precursor inhibitor pair enhances TMZ cytotoxicity in vitro and in vivo, respectively, and do so in a p53-dependent manner.

Original languageEnglish (US)
Pages (from-to)10034-10039
Number of pages6
JournalCancer Research
Volume68
Issue number24
DOIs
StatePublished - Dec 15 2008

Fingerprint

temozolomide
Glioblastoma
Heterografts
Poly(ADP-ribose) Polymerases
Survival Analysis
Nude Mice
Cell Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

p53 small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. / Dinca, Eduard B.; Lu, Kan V.; Sarkaria, Jann N; Pieper, Russell O.; Prados, Michael D.; Haas-Kogan, Daphne A.; VandenBerg, Scott R.; Berger, Mitchel S.; James, C. David.

In: Cancer Research, Vol. 68, No. 24, 15.12.2008, p. 10034-10039.

Research output: Contribution to journalArticle

Dinca, EB, Lu, KV, Sarkaria, JN, Pieper, RO, Prados, MD, Haas-Kogan, DA, VandenBerg, SR, Berger, MS & James, CD 2008, 'p53 small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts', Cancer Research, vol. 68, no. 24, pp. 10034-10039. https://doi.org/10.1158/0008-5472.CAN-08-1687
Dinca, Eduard B. ; Lu, Kan V. ; Sarkaria, Jann N ; Pieper, Russell O. ; Prados, Michael D. ; Haas-Kogan, Daphne A. ; VandenBerg, Scott R. ; Berger, Mitchel S. ; James, C. David. / p53 small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. In: Cancer Research. 2008 ; Vol. 68, No. 24. pp. 10034-10039.
@article{cca935beb8304963a0ba5e4adccddb85,
title = "p53 small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts",
abstract = "In this study, we investigated the precursor and active forms of a p53 small-molecule inhibitor for their effects on temozolomide (TMZ) antitumor activity against glioblastoma (GBM), using both in vitro and in vivo experimental approaches. Results from in vitro cell viability analysis showed that the cytotoxic activity of TMZ was substantially increased when p53 wild-type (p53wt) GBMs were cotreated with the active form of p53 inhibitor, and this heightened cytotoxic response was accompanied by increased poly(ADP-ribose) polymerase cleavage as well as elevated cellular phospho-H2AX. Analysis of the same series of GBMs, as intracranial xenografts in athymic mice, and administering corresponding p53 inhibitor precursor, which is converted to the active compound in vivo, yielded results consistent with the in vitro analyses: TMZ + p53 inhibitor precursor cotreatment of three distinct p53 wt GBM xenografts resulted in significant enhancement of TMZ antitumor effect relative to treatment with TMZ alone, as indicated by serial bioluminescence monitoring as well as survival analysis (P < 0.001 for cotreatment survival benefit in each case). Mice receiving intracranial injection with p53null GBM showed similar survival benefit from TMZ treatment regardless of the presence or absence of p53 inhibitor precursor. In total, our results indicate that the p53 active and precursor inhibitor pair enhances TMZ cytotoxicity in vitro and in vivo, respectively, and do so in a p53-dependent manner.",
author = "Dinca, {Eduard B.} and Lu, {Kan V.} and Sarkaria, {Jann N} and Pieper, {Russell O.} and Prados, {Michael D.} and Haas-Kogan, {Daphne A.} and VandenBerg, {Scott R.} and Berger, {Mitchel S.} and James, {C. David}",
year = "2008",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-08-1687",
language = "English (US)",
volume = "68",
pages = "10034--10039",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - p53 small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts

AU - Dinca, Eduard B.

AU - Lu, Kan V.

AU - Sarkaria, Jann N

AU - Pieper, Russell O.

AU - Prados, Michael D.

AU - Haas-Kogan, Daphne A.

AU - VandenBerg, Scott R.

AU - Berger, Mitchel S.

AU - James, C. David

PY - 2008/12/15

Y1 - 2008/12/15

N2 - In this study, we investigated the precursor and active forms of a p53 small-molecule inhibitor for their effects on temozolomide (TMZ) antitumor activity against glioblastoma (GBM), using both in vitro and in vivo experimental approaches. Results from in vitro cell viability analysis showed that the cytotoxic activity of TMZ was substantially increased when p53 wild-type (p53wt) GBMs were cotreated with the active form of p53 inhibitor, and this heightened cytotoxic response was accompanied by increased poly(ADP-ribose) polymerase cleavage as well as elevated cellular phospho-H2AX. Analysis of the same series of GBMs, as intracranial xenografts in athymic mice, and administering corresponding p53 inhibitor precursor, which is converted to the active compound in vivo, yielded results consistent with the in vitro analyses: TMZ + p53 inhibitor precursor cotreatment of three distinct p53 wt GBM xenografts resulted in significant enhancement of TMZ antitumor effect relative to treatment with TMZ alone, as indicated by serial bioluminescence monitoring as well as survival analysis (P < 0.001 for cotreatment survival benefit in each case). Mice receiving intracranial injection with p53null GBM showed similar survival benefit from TMZ treatment regardless of the presence or absence of p53 inhibitor precursor. In total, our results indicate that the p53 active and precursor inhibitor pair enhances TMZ cytotoxicity in vitro and in vivo, respectively, and do so in a p53-dependent manner.

AB - In this study, we investigated the precursor and active forms of a p53 small-molecule inhibitor for their effects on temozolomide (TMZ) antitumor activity against glioblastoma (GBM), using both in vitro and in vivo experimental approaches. Results from in vitro cell viability analysis showed that the cytotoxic activity of TMZ was substantially increased when p53 wild-type (p53wt) GBMs were cotreated with the active form of p53 inhibitor, and this heightened cytotoxic response was accompanied by increased poly(ADP-ribose) polymerase cleavage as well as elevated cellular phospho-H2AX. Analysis of the same series of GBMs, as intracranial xenografts in athymic mice, and administering corresponding p53 inhibitor precursor, which is converted to the active compound in vivo, yielded results consistent with the in vitro analyses: TMZ + p53 inhibitor precursor cotreatment of three distinct p53 wt GBM xenografts resulted in significant enhancement of TMZ antitumor effect relative to treatment with TMZ alone, as indicated by serial bioluminescence monitoring as well as survival analysis (P < 0.001 for cotreatment survival benefit in each case). Mice receiving intracranial injection with p53null GBM showed similar survival benefit from TMZ treatment regardless of the presence or absence of p53 inhibitor precursor. In total, our results indicate that the p53 active and precursor inhibitor pair enhances TMZ cytotoxicity in vitro and in vivo, respectively, and do so in a p53-dependent manner.

UR - http://www.scopus.com/inward/record.url?scp=57749090260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57749090260&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-1687

DO - 10.1158/0008-5472.CAN-08-1687

M3 - Article

C2 - 19074867

AN - SCOPUS:57749090260

VL - 68

SP - 10034

EP - 10039

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 24

ER -